1. Novartis and NHS' inclisiran tie-up gets big billing  The Pharma Letter
  2. NHS to Fast Track as Yet Unapproved Cholesterol Drug  Medscape
  3. UK’s NHS teams with Novartis to launch heart attack drug trial  Financial Times
  4. New cholesterol 'vaccine' could save thousands of lives a year  The Times
  5. 'Game-changing' heart disease drug 'could save 30,000 lives' over the next decade  Mirror Online
  6. View full coverage on Google News
Swiss pharma giant Novartis has announced a deal with the National Health Service (NHS) that will bring English patients with atherosclerotic cardiovascular dis

Novartis and NHS’ inclisiran tie-up gets big billing

The NHS in England has agreed early access to a new cholesterol drug in a collaboration with the manufacturer.The NHS in England has agreed early access to a new cholesterol drug in a collaboration with the manufacturer.

NHS to Fast Track as Yet Unapproved Cholesterol Drug

Patients should soon have access to a new cholesterol-lowering treatment for preventing heart attacks and strokes as Government plans for it to become widely available on the NHS Patients should soon have access to a new cholesterol-lowering treatment for preventing heart attacks and strokes as Government plans for it to become widely available on the NHS

'Game-changing' heart disease drug 'could save 30,000 lives' over the next decade - Mirror Online

Thousands of NHS patients in England could this year join a clinical trial to get access to a six-monthly injection to lower their cholesterol and the drug could be widely available next year.Thousands of NHS patients in England could this year join a clinical trial to get access to a six-monthly injection to lower their cholesterol and the drug could be widely available next year.

Experimental cholesterol jab to be given to thousands of NHS patients at risk of heart disease | Daily Mail Online

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

Subscribe to read | Financial Times

Britain's National Health Service (NHS) announced an agreement with pharmaceutical giant Novartis (NYSE: NVS) to help accelerate the review process for its heart drug inclisiran. The agreement would see inclisiran provided to patients who are at high risk of cardiovascular inci

Novartis' Heart Drug Gets Accelerated Review in Britain for High-Risk Patients | Nasdaq

A “vaccine” for high cholesterol that would replace daily statins and save 30,000 lives over ten years is scheduled to be available on the NHS next year.The government has announced a deal with the pharmaceutical company Novartis to conduct a large NHS trial of inclisiran, which has been found by eaA “vaccine” for high cholesterol that would replace daily statins and save 30,000 lives over ten years is scheduled to be available on the NHS next year. The government has announced a deal with...

New cholesterol ‘vaccine’ could save thousands of lives a year | News | The Times

The Swiss drugmaker will provide the drug to patients with atherosclerosis, a heart disease in which plaque builds up inside arteries and can lead to problems, including heart attack or death.The Swiss drugmaker will provide the drug to patients with atherosclerosis, a heart disease in which plaque builds up inside arteries and can lead to problems, including heart attack or death.

Novartis CEO Vas Narasimhan and British health officials have struck a deal to get the drugmaker's as-yet-unapproved cholesterol drug, inclisiran, to thousands of NHS patients. The "population-level" agreement, unveiled Monday at JPM, could pose a threat to PCSK9 rivals Repatha and Praluent while heralding a reimbursement scheme for other payers, too.Novartis CEO Vas Narasimhan and British health officials have struck a deal to get the drugmaker's as-yet-unapproved cholesterol drug, inclisiran, to thousands of NHS patients. The "population-level" agreement, unveiled Monday at JPM, could pose a threat to PCSK9 rivals Repatha and Praluent while heralding a reimbursement scheme for other payers, too.

JPM: Novartis teams up with NHS England in 'world-first' access deal for PCSK9 hopeful inclisiran | FiercePharma

The deal will make the Phase III drug inclisiran - which Novartis acquired when it bought The Medicines Company in November - available to patients in the U.K. and include manufacturing and clinical development efforts. The deal will make the Phase III drug inclisiran - which Novartis acquired when it bought The Medicines Company in November - available to patients in the U.K. and include manufacturing and clinical development efforts.

Novartis, UK's NHS form population health partnership around new cholesterol drug - MedCity News

A jab which is more powerful than statins has been given the go-ahead by the NHS, in a bid to prevent 30,000 deaths from heart attacks and strokes.A jab which is more powerful than statins has been given the go-ahead by the NHS, in a bid to prevent 30,000 deaths from heart attacks and strokes.

Heart jab which can halve bad cholesterol in two weeks gets NHS green light 

The government is collaborating with pharmaceutical company Novartis to launch a clinical trial for new cholesterol treatment.The government is collaborating with pharmaceutical company Novartis to launch a clinical trial for new cholesterol treatment.

Novartis and Britain's National Health Service (NHS) on Monday announced a pact that will clear the way for accelerated review by the country's health watchdog NICE for heart drug inclisiran, which could make it broadly available as soon as 2021.Novartis and Britain's National Health Service (NHS) on Monday announced a ...

Novartis to speed access to $10 billion heart drug via NHS deal - Reuters